Pagets (Bone) disease

Related Subjects: | Bisphosphonates | Osteoporosis | Calcium Physiology | Bisphosphonates | Osteonecrosis of the Jaw

🦴 Paget’s Disease of Bone is a chronic disorder of bone remodelling characterised by excessive osteoclast-mediated bone resorption followed by disorganized osteoblast activity. The resulting bone is structurally weak, enlarged, and prone to deformity. It is the second most common metabolic bone disease after osteoporosis and predominantly affects older adults in the UK and Europe.

About 🔎

• Disorder of bone remodelling → focal areas of increased osteoclastic resorption followed by chaotic osteoblastic repair.
• Prevalence rises with age: rare <50 years, ~5% of adults >55 years in the UK.
• Strong geographic clustering: more common in UK, Western Europe, and North America.
• Often discovered incidentally via raised ALP or characteristic X-ray findings.
• May be monostotic (single bone) or polyostotic (multiple bones).

Aetiology 🧬

• Exact cause uncertain; interplay of genetic and environmental factors likely.
• Mutations in SQSTM1 gene found in familial cases; other loci may be involved.
• Possible viral triggers: paramyxovirus particles detected in osteoclasts in some studies.
• Histology: enlarged osteoclasts with multiple nuclei and inclusion bodies, disorganized lamellar bone.

Pathophysiology ⚡

• Normal bone undergoes continuous remodelling via osteoclasts and osteoblasts.
• In Paget’s: osteoclast activity ↑↑ → excessive bone resorption, followed by abnormal, disorganized osteoblastic bone formation.
• Results in structurally weak, enlarged, hypervascular bone prone to deformity and fracture.
• High bone turnover may occasionally cause high-output cardiac failure in extensive disease.

Clinical Features 🦴

• Often asymptomatic; incidental detection on raised ALP.
• Bone pain – dull, persistent, often worse at night; may be due to microfractures or secondary arthritis.
• Bone deformity: bowed tibia (“sabre tibia”), kyphosis, skull enlargement → increasing hat size.
• Neurological: deafness (conductive + sensorineural), cranial nerve palsies, spinal stenosis, radiculopathy.
• Fractures: pathologic fractures in affected bones.
• Complications: secondary osteoarthritis, high-output cardiac failure (rare), osteosarcoma/fibrosarcoma (~1%, poor prognosis).
• Other: warmth over affected bones due to hypervascularity.

Investigations 🧪

• Bloods: isolated raised ALP (liver function normal), normal calcium and phosphate; consider bone turnover markers (P1NP, CTX) in research settings.
• Urine: hydroxyproline ↑ (bone resorption marker) if needed.
• X-ray: mixed lytic/sclerotic lesions, cortical thickening, bone enlargement, classic “cotton wool skull.”
• Bone scan (Tc-99m MDP): highly sensitive to detect disease extent; “hot spots” indicate active lesions.
• DEXA: may show increased bone density locally; not used for diagnosis but may guide fracture risk.
• CT/MRI: reserved for complications (neurocompression, suspected sarcoma).

Complications ⚠️

• Pathologic fractures
• Secondary osteoarthritis and deformity
• Hearing loss / cranial nerve compression
• High-output cardiac failure (extensive polyostotic disease)
• Osteosarcoma or fibrosarcoma (rare, ~1%)

Management 💊 (NICE-aligned)

Monitoring & Follow-up 🔍

• ALP every 6–12 months to assess biochemical response to therapy.
• Repeat imaging if new pain, deformity, or suspicion of sarcomatous change.
• Assess and correct vitamin D deficiency before bisphosphonate therapy.
• Long-term follow-up to monitor complications, especially in polyostotic disease.

Exam Tips 🎓

• Think of Paget’s with isolated high ALP in older adults with normal calcium.
• “Cotton wool skull” on X-ray is a classic buzzword.
• Paget’s triad: bone pain + deformity + hearing loss.
• Differentiate from osteoporosis (diffuse bone thinning, normal ALP) and osteomalacia (low vitamin D/Ca, raised ALP).
• Zoledronate single-dose IV often curative for symptomatic lesions.

References 📚

• UK Paget’s Association Clinical Guidelines
• BMJ Best Practice: Paget’s Disease
• NICE NG183: Osteoporosis & metabolic bone disease guidance